These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33199516)

  • 1. The Implications of Chromatographically Screening Medical Products for Organic Leachables Down to the Analytical Evaluation Threshold Adjusted for Response Factor Variation.
    Jenke D; Heise T
    PDA J Pharm Sci Technol; 2021; 75(3):273-288. PubMed ID: 33199516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Analytical Strategy Based on Multiple Complementary and Orthogonal Chromatographic and Detection Methods (Multidetector Approach) to Effectively Manage the Analytical Evaluation Threshold (AET).
    Jordi M; Heise T
    PDA J Pharm Sci Technol; 2021; 75(3):289-301. PubMed ID: 33199517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Practical Derivation of the Uncertainty Factor Applied to Adjust the Extractables/Leachables Analytical Evaluation Threshold (AET) for Response Factor Variation.
    Jenke D; Christiaens P; Beusen JM; Verlinde P; Baeten J
    PDA J Pharm Sci Technol; 2022; 76(3):178-199. PubMed ID: 34782443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
    Jenke D; Carlson T
    PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and quantification of medical device extractables and leachables via non-target analysis (NTA); Analytical uncertainty.
    Jenke D; Christiaens P; Heise T
    J Pharm Biomed Anal; 2024 Apr; 241():115985. PubMed ID: 38301578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correcting the Analytical Evaluation Threshold (AET) and Reported Extractable's Concentrations for Analytical Response Factor Uncertainty Associated with Chromatographic Screening for Extractables/Leachables.
    Jenke D
    PDA J Pharm Sci Technol; 2020; 74(3):348-358. PubMed ID: 32295860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying and Mitigating Errors in Screening for Organic Extractables and Leachables: Part 1-Introduction to Errors in Chromatographic Screening for Organic Extractables and Leachables and Discussion of the Errors of Omission.
    Christiaens P; Beusen JM; Verlinde P; Baeten J; Jenke D
    PDA J Pharm Sci Technol; 2020; 74(1):90-107. PubMed ID: 31209164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing relative response factor variation using a multidetector approach for extractables and leachables (E&L) analysis to mitigate the need for uncertainty factors.
    Jordi MA; Rowland K; Liu W; Cao X; Zong J; Ren Y; Liang Z; Zhou X; Louis M; Lerner K
    J Pharm Biomed Anal; 2020 Jul; 186():113334. PubMed ID: 32387747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardization of Chromatographic Screening Methods for Organic Extractables and Leachables by Managing Outcomes.
    Jenke D
    PDA J Pharm Sci Technol; 2023; 77(4):329-338. PubMed ID: 37001885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on the PQRI Extractables and Leachables "Safety Thresholds and Best Practices" Recommendations for Inhalation Drug Products.
    Norwood DL; Nagao LM; Stults CL
    PDA J Pharm Sci Technol; 2013; 67(5):413-29. PubMed ID: 24084658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying and Mitigating Errors in Screening for Organic Extractables and Leachables: Part 2-Errors of Inexact Identification and Inaccurate Quantitation.
    Christiaens P; Beusen JM; Verlinde P; Baeten J; Jenke D
    PDA J Pharm Sci Technol; 2020; 74(1):108-133. PubMed ID: 31308065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Retention Time and/or Structure Matching a Solution to the Challenge of Providing Quantitative Data When Screening for Extractables and Leachables by GC/MS?
    Jenke D; Christiaens P; Verlinde P; Baeten J; Beusen JM
    PDA J Pharm Sci Technol; 2022; 76(3):236-247. PubMed ID: 34782445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extractables and leachables considerations for prefilled syringes.
    Jenke DR
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1591-600. PubMed ID: 24955780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Product Quality Research Institute (PQRI) Leachables and Extractables Working Group Initiatives for Parenteral and Ophthalmic Drug Product (PODP).
    Paskiet D; Jenke D; Ball D; Houston C; Norwood DL; Markovic I
    PDA J Pharm Sci Technol; 2013; 67(5):430-47. PubMed ID: 24084659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Safety Risk-Based Extractables and/or Leachables Qualification Strategy for Packaged Drug Products.
    Jenke D
    PDA J Pharm Sci Technol; 2021; 75(6):506-535. PubMed ID: 33990423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying and Mitigating Errors in Screening for Organic Extractables and Leachables: Part 3-Considering Errors of Implementation and the Use of a Database to Judge and Promote Good Science and Efficient Practices.
    Jenke D
    PDA J Pharm Sci Technol; 2020; 74(1):134-146. PubMed ID: 31209166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative assessment of extractables from single-use components and the impact of reference standard selection.
    Jordi MA; Khera S; Roland K; Jiang L; Solomon P; Nelson J; Lateef SS; Woods J; Martin L; Martin S; Aiello F; Chen N
    J Pharm Biomed Anal; 2018 Feb; 150():368-376. PubMed ID: 29287264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate or Protective: What Is the Goal of Non-Targeted Extractables and Leachables Quantitation and Identification?
    Jenke D
    PDA J Pharm Sci Technol; 2024 Jun; 78(3):358-366. PubMed ID: 37973191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of TOC Reconciliation as a Means of Establishing the Degree to Which Chromatographic Screening of Plastic Material Extracts for Organic Extractables Is Complete.
    Jenke D; Couch TR; Robinson SJ; Volz TJ; Colton RH
    PDA J Pharm Sci Technol; 2014; 68(3):256-70. PubMed ID: 25188347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.